SLDB
Solid BiosciencesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
SLDB vs peer average
56/100
SLDB vs. peer average (C vs. C)
Grade spread
A 1 · B 1 · C 4 · D 3 · F 2
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
SRPT is the first available peer comparator.
Sarepta is the clearest commercial comparator because ELEVIDYS is described by the company as the first and only approved gene therapy for Duchenne muscular dystrophy, which keeps competitive and regulatory pressure high for any emerging microdystrophin program.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
SLDB
Solid Biosciences
SRPT
Sarepta Therapeutics
Grade
C
B
Momentum
86
85
Value
41
51
Sentiment
55
65
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Constructive
Grade position vs SRPT
SLDB / SRPT
Grade Position
In line
SLDB vs. peer average (C vs. C)
56/100
Momentum
86
SLDBValue
41
SRPTSentiment
55
SRPTRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs SLDB
SRPT is the first peer returned for this comparison set.